TY  - JOUR
AU  - Yubero, Alfonso
AU  - Barquín, Aranzazu
AU  - Estévez, Purificación
AU  - Pajares, Bella
AU  - Sánchez, Luisa
AU  - Reche, Piedad
AU  - Alarcón, Jesús
AU  - Calzas, Julia
AU  - Gaba, Lydia
AU  - Fuentes, José
AU  - Santaballa, Ana
AU  - Salvador, Carmen
AU  - Manso, Luis
AU  - Herrero, Ana
AU  - Taus, Álvaro
AU  - Márquez, Raúl
AU  - Madani, Julia
AU  - Merino, María
AU  - Marquina, Gloria
AU  - Casado, Victoria
AU  - Constenla, Manuel
AU  - Gutiérrez, María
AU  - Dosil, Alba
AU  - González-Martín, Antonio
PY  - 2022
DO  - 10.1186/s12885-022-10191-5
UR  - http://hdl.handle.net/10668/20283
T2  - BMC cancer
AB  - Rucaparib is a poly(ADP-ribose) polymerase inhibitor approved in Europe as maintenance therapy for recurrent platinum-sensitive (Pt-S) ovarian cancer (OC). The Rucaparib Access Programme (RAP) was designed to provide early access to rucaparib for the...
LA  - en
KW  - Maintenance
KW  - PARP inhibitor
KW  - Recurrent ovarian cancer
KW  - Rucaparib
KW  - Treatment
KW  - Humans
KW  - Female
KW  - Spain
KW  - Ovarian Neoplasms
KW  - Retrospective Studies
KW  - Neoplasm Recurrence, Local
KW  - Carcinoma, Ovarian Epithelial
KW  - Poly(ADP-ribose) Polymerase Inhibitors
KW  - Antineoplastic Agents
TI  - Rucaparib in recurrent ovarian cancer: real-world experience from the rucaparib early access programme in Spain - A GEICO study.
TY  - research article
VL  - 22
ER  -